---
schema_version: "secwatch.filing_event.v1"
accession: "0001847903-23-000192"
form_type: "8-K"
ticker: "CNTA"
cik: "0001847903"
company_name: "Centessa Pharmaceuticals plc"
filed_at: "2023-12-11T23:59:59+00:00"
generated_at: "2026-06-07T15:05:08.517058+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Centessa SerpinPC Phase 2a Part 5 results: 96% median ABR reduction

## Summary
- Median all-bleed ABR of 1.0, a 96% reduction from prospective baseline of 35.6.
- No thromboembolic events or treatment-related sustained D-dimer elevations observed.
- Total target joints reduced by 94% (from 53 to 3) by end of Part 5.
- Registrational PRESent-2 and PRESent-3 studies for hemophilia B are ongoing.
- No SerpinPC-related adverse events reported in Part 5; favorable safety profile.

## SEC filing metadata
- accession: 0001847903-23-000192
- form_type: 8-K
- ticker: CNTA
- cik: 0001847903
- company_name: Centessa Pharmaceuticals plc
- filed_at: 2023-12-11T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1847903/000184790323000192/0001847903-23-000192-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1847903/000184790323000192/cnta-20231210.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001847903-23-000192
- JSON: https://secwatch.observer/filing/0001847903-23-000192.json
- Plain text: https://secwatch.observer/filing/0001847903-23-000192.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.